Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Aardvark Therapeutics, Inc. on August 14, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (June 18, 2026), 21,884,158 shares were outstanding. A quorum was established with 11,992,479 shares represented (approximately 54.79%). Stockholders voted on three proposals:
- Proposal 1 (Election of Directors): Stockholders elected Victor Tong, Jr. and Jeffrey Chi, Ph.D. as Class I directors to serve until the 2029 annual meeting.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
- Proposal 3 (Option Repricing): Stockholders approved the repricing of certain outstanding stock options under the 2017 Plan, 2025 Plan, and 2025 Inducement Plan held by Eligible Participants.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the voting results.
Key Facts for Investor Verification
- Verify the specific terms and financial impact of the approved stock option repricing (Proposal 3) in the definitive proxy statement filed on July 10, 2026.
- Confirm the dilution impact of the repriced options on existing shareholders.
- Review the full voting breakdown, noting that Proposal 3 received significant opposition (3,439,983 votes against) compared to the other proposals.
- Check subsequent filings for the Company's financial position, as this 8-K contains no financial data.